Autonomix Medical, Inc. (NASDAQ:AMIX)
| Market Cap | 1.85M-86.7% |
| Revenue (ttm) | 0 |
| Net Income | -16.11M-33.7% |
| EPS | -46.49+64.8% |
| Shares Out | 543.00K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 55,960 |
| Open | 3.50 |
| Previous Close | 3.47 |
| Day's Range | 3.39 - 3.59 |
| 52-Week Range | 2.44 - 32.55 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Nov 11, 2026 |
Insiders here have filed 4 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About AMIX
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company’s technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.
$AMIX stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in AMIX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by AMIX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
AMIX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New AMIX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to AMIX from public contracts
Source: USAspending.gov
AMIX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from AMIX’s recent data — informational, not investment advice
